Timothy Cundy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9522647/publications.pdf

Version: 2024-02-01

104 papers	7,309 citations	57758 44 h-index	54911 84 g-index
106 all docs	106 docs citations	106 times ranked	8636 citing authors

#	Article	IF	Citations
1	LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development. Cell, 2001, 107, 513-523.	28.9	2,055
2	Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Human Molecular Genetics, 2002, 11, 2735-2739.	2.9	307
3	Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nature Genetics, 2010, 42, 520-524.	21.4	258
4	A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Human Molecular Genetics, 2002, 11, 2119-2127.	2.9	190
5	Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. American Journal of Medicine, 1996, 101, 341-348.	1.5	164
6	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nature Genetics, 2011, 43, 685-689.	21.4	158
7	Novel UBA Domain Mutations of SQSTM1 in Paget's Disease of Bone: Genotype Phenotype Correlation, Functional Analysis, and Structural Consequences. Journal of Bone and Mineral Research, 2004, 19, 1122-1127.	2.8	142
8	Enhanced RANK ligand expression and responsivity of bone marrow cells in Pagetâ€™s disease of bone. Journal of Clinical Investigation, 2000, 105, 1833-1838.	8.2	142
9	Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen. Human Molecular Genetics, 2013, 22, 1-17.	2.9	135
10	Depot Medroxyprogesterone Acetate and Bone Mineral Density in Adolescentsâ€”The Black Box Warning: A Position Paper of the Society for Adolescent Medicine. Journal of Adolescent Health, 2006, 39, 296-301.	2.5	127
11	Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. BMJ, The, 2014, 348, g1567-g1567.	6.0	122
12	Genomewide Search in Familial Paget Disease of Bone Shows Evidence of Genetic Heterogeneity with Candidate Loci on Chromosomes 2q36, 10p13, and 5q35. American Journal of Human Genetics, 2001, 69, 1055-1061.	6.2	113
13	Idiopathic Hyperphosphatasia andTNFRSF11BMutations: Relationships Between Phenotype and Genotype. Journal of Bone and Mineral Research, 2003, 18, 2095-2104.	2.8	113
14	Sources of interracial variation in bone mineral density. Journal of Bone and Mineral Research, 1995, 10, 368-373.	2.8	100
15	Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone, 2004, 35, 224-230.	2.9	99
16	Sequence Analysis of Measles Virus Nucleocapsid Transcripts in Patients with Paget's Disease. Journal of Bone and Mineral Research, 2002, 17, 145-151.	2.8	95
17	Ethnic differences in illness perceptions, self-efficacy and diabetes self-care. Psychology and Health, 2007, 22, 787-811.	2.2	92
18	Recombinant Osteoprotegerin for Juvenile Paget's Disease. New England Journal of Medicine, 2005, 353, 918-923.	27.0	89

#	Article	IF	Citations
19	Proton pump inhibitors and severe hypomagnesaemia. Current Opinion in Gastroenterology, 2011, 27, 180-185.	2.3	89
20	The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clinical Endocrinology, 1998, 49, 615-618.	2.4	88
21	Recent Advances in Osteogenesis Imperfecta. Calcified Tissue International, 2012, 90, 439-449.	3.1	88
22	Spinal bone density in women using depot medroxyprogesterone contraception*1. Obstetrics and Gynecology, 1998, 92, 569-573.	2.4	86
23	A Randomized Controlled Trial of Estrogen Replacement Therapy in Long-Term Users of Depot Medroxyprogesterone Acetate. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 78-81.	3.6	82
24	1,25-Dihydroxyvitamin D3 Hypersensitivity of Osteoclast Precursors from Patients with Paget's Disease. Journal of Bone and Mineral Research, 2010, 15, 228-236.	2.8	81
25	Differential Gene Expression in Cultured Osteoblasts and Bone Marrow Stromal Cells From Patients With Paget's Disease of Bone. Journal of Bone and Mineral Research, 2006, 22, 298-309.	2.8	76
26	The Effect of an Apparent Change to a Branded or Generic Medication on Drug Effectiveness and Side Effects. Psychosomatic Medicine, 2013, 75, 90-96.	2.0	75
27	Delayed Development of Paget's Disease in Offspring InheritingSQSTM1Mutations. Journal of Bone and Mineral Research, 2007, 22, 411-415.	2.8	73
28	Differing Causes of Pregnancy Loss in Type 1 and Type 2 Diabetes. Diabetes Care, 2007, 30, 2603-2607.	8.6	72
29	Impact of television coverage on the number and type of symptoms reported during a health scare: a retrospective preâ€“post observational study. BMJ Open, 2012, 2, e001607.	1.9	64
30	Failure to Detect Measles Virus Ribonucleic Acid in Bone Cells from Patients with Pagetâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1398-1401.	3.6	60
31	Susceptibility to Paget's Disease of Bone Is Influenced by a Common Polymorphic Variant of Osteoprotegerin. Journal of Bone and Mineral Research, 2004, 19, 1506-1511.	2.8	59
32	Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. American Journal of Obstetrics and Gynecology, 2002, 186, 978-983.	1.3	58
33	Paget's disease of bone. Metabolism: Clinical and Experimental, 2018, 80, 5-14.	3.4	58
34	Thyroxine: anatomy of a health scare. BMJ: British Medical Journal, 2009, 339, b5613-b5613.	2.3	56
35	The power of positive and negative expectations to influence reported symptoms and mood during exposure to wind farm sound.. Health Psychology, 2014, 33, 1588-1592.	1.6	56
36	Insulin Sensitivity in the Offspring of Women With Type 1 and Type 2 Diabetes. Diabetes Care, 2004, 27, 1148-1152.	8.6	53

#	Article	IF	Citations
37	Paget disease of bone. Trends in Endocrinology and Metabolism, 2008, 19, 246-253.	7.1	52
38	Treatment of Idiopathic Hyperphosphatasia With Intensive Bisphosphonate Therapy. Journal of Bone and Mineral Research, 2004, 19, 703-711.	2.8	51
39	Role of TAFII-17, a VDR Binding Protein, in the Increased Osteoclast Formation in Paget's Disease. Journal of Bone and Mineral Research, 2004, 19, 1154-1164.	2.8	49
40	Reversible Deterioration in Hypophosphatasia Caused by Renal Failure With Bisphosphonate Treatment. Journal of Bone and Mineral Research, 2015, 30, 1726-1737.	2.8	48
41	Osteoporosis pseudoglioma syndrome: Treatment of spinal osteoporosis with intravenous bisphosphonates. Journal of Pediatrics, 2000, 137, 410-415.	1.8	47
42	Identification of a Major Locus for Paget's Disease on Chromosome 10p13 in Families of British Descent. Journal of Bone and Mineral Research, 2008, 23, 58-63.	2.8	47
43	Paget's disease of bone: clinical review and update. Journal of Clinical Pathology, 2013, 66, 924-927.	2.0	47
44	Paget's disease of bone--becoming a rarity?. Rheumatology, 2009, 48, 1232-1235.	1.9	46
45	Ubiquitin-Associated Domain Mutations of SQSTM1 in Paget's Disease of Bone: Evidence for a Founder Effect in Patients of British Descent. Journal of Bone and Mineral Research, 2004, 20, 227-231.	2.8	45
46	Peak Bone Mass After Exposure to Antenatal Betamethasone and Prematurity: Follow-up of a Randomized Controlled Trial. Journal of Bone and Mineral Research, 2006, 21, 1175-1186.	2.8	45
47	Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. Clinical Endocrinology, 1996, 44, 293-296.	2.4	44
48	Is the Prevalence of Paget's Disease of Bone Decreasing?. Journal of Bone and Mineral Research, 2006, 21, P9-P13.	2.8	44
49	Osteonecrosis of the jaw. Skeletal Radiology, 2009, 38, 5-9.	2.0	44
50	Spinal Bone Density in Women Using Depot Medroxyprogesterone Contraception. Obstetrics and Gynecology, 1998, 92, 569-573.	2.4	39
51	Evaluation of the role of Valosin-containing protein in the pathogenesis of familial and sporadic Paget's disease of bone. Bone, 2006, 38, 280-285.	2.9	38
52	Paget's disease of bone. Clinical Biochemistry, 2012, 45, 43-48.	1.9	38
53	Referrals to Psychiatrists in a General Hospital â€" Comparison of Two Methods of Liaison Psychiatry: Preliminary Communication. Journal of the Royal Society of Medicine, 1985, 78, 463-468.	2.0	37
54	Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. Experimental Hematology, 1999, 27, 1528-1532.	0.4	37

#	Article	IF	Citations
55	Presentation, pathology and prognosis of renal disease in type 2 diabetes. BMJ Open Diabetes Research and Care, 2017, 5, e000412.	2.8	33
56	Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone. Journal of Bone and Mineral Research, 2017, 32, 753-756.	2.8	33
57	Juvenile Paget disease. Metabolism: Clinical and Experimental, 2018, 80, 15-26.	3.4	32
58	Absence of Somatic SQSTM1 Mutations in Pagetâ€™s Disease of Bone. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 691-694.	3.6	31
59	Skeletal phenotype of mandibuloacral dysplasia associated with mutations in ZMPSTE24. Bone, 2010, 47, 591-597.	2.9	31
60	The Link between Health Complaints and Wind Turbines: Support for the Nocebo Expectations Hypothesis. Frontiers in Public Health, 2014, 2, 220.	2.7	31
61	Determinants of Birth-weight in Women with Established and Gestational Diabetes. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1993, 33, 249-254.	1.0	30
62	Ocular Manifestations of Juvenile Paget Disease. JAMA Ophthalmology, 2010, 128, 698.	2.4	29
63	Establishing Consensus in the Diagnosis of Gestational Diabetes Following HAPO: Where Do We Stand?. Current Diabetes Reports, 2013, 13, 43-50.	4.2	29
64	Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1Î±,25-dihydroxyvitamin D3 from pagetic bone marrow cells. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 331-334.	2.5	27
65	Evolution of Paget's disease of bone in adults inheriting <scp>SQSTM</scp>1 mutations. Clinical Endocrinology, 2015, 83, 315-319.	2.4	26
66	Fetal liver length in diabetic pregnancy. American Journal of Obstetrics and Gynecology, 1994, 170, 1308-1312.	1.3	25
67	Attrition after Acceptance onto a Publicly Funded Bariatric Surgery Program. Obesity Surgery, 2018, 28, 2500-2507.	2.1	25
68	Fetal liver length in diabetic pregnancy. American Journal of Obstetrics and Gynecology, 1994, 170, 1308-1312.	1.3	23
69	Paget's disease in patients of Asian descent in New Zealand. Journal of Bone and Mineral Research, 2012, 27, 223-226.	2.8	23
70	Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta. Clinical Chemistry, 2007, 53, 1109-1114.	3.2	22
71	Addition of Monofluorophosphate to Estrogen Therapy in Postmenopausal Osteoporosis: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2446-2452.	3.6	21
72	Mutations That Alter the Carboxy-Terminal-Propeptide Cleavage Site of the Chains of Type I Procollagen Are Associated With a Unique Osteogenesis Imperfecta Phenotype. Journal of Bone and Mineral Research, 2018, 33, 1260-1271.	2.8	21

#	Article	IF	Citations
73	Low-dose Fluoride in Postmenopausal Women: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2301-2307.	3.6	20
74	Novel homozygous mutations in the osteoprotegerin gene TNFRSF11B in two unrelated patients with juvenile Paget's disease. Bone, 2014, 68, 6-10.	2.9	18
75	Evidence of a Media-Induced Nocebo Response Following a Nationwide Antidepressant Drug Switch. Clinical Psychology in Europe, 2019, 1, .	1.1	17
76	Bisphosphonate Use and Fractures in Adults with Hypophosphatasia. JBMR Plus, 2019, 3, e10223.	2.7	16
77	Early Worsening of Diabetic Nephropathy in Type 2 Diabetes After Rapid Improvement in Chronic Severe Hyperglycemia. Diabetes Care, 2021, 44, e55-e56.	8.6	16
78	Rapid suppression of plasma alkaline phosphatase activity after renal transplantation in patients with osteodystrophy. Clinica Chimica Acta, 1987, 164, 285-291.	1.1	15
79	Glomerular hyperfiltration in young Polynesians with type 2 diabetes. Diabetes Research and Clinical Practice, 1994, 25, 155-160.	2.8	15
80	Familial Paget Disease and SQSTM1 Mutations in New Zealand. Calcified Tissue International, 2011, 89, 258-264.	3.1	13
81	Reprint: Paget's disease of bone. Clinical Biochemistry, 2012, 45, 970-975.	1.9	12
82	Pregnancy loss and neonatal death in women with type 1 or type 2 diabetes mellitus. Insulin, 2008, 3, 167-175.	0.2	11
83	Response to publication of PRISM trial. Journal of Bone and Mineral Research, 2010, 25, 1463-1464.	2.8	9
84	Proteinuric renal disease in type 2 diabetesâ€"Is remission of proteinuria associated with improved mortality and morbidity?. Diabetes Research and Clinical Practice, 2014, 103, 63-70.	2.8	8
85	Long-Term Effects of Intravenous Ibandronate in Pagetâ€™s Disease of Bone. Calcified Tissue International, 2017, 100, 250-254.	3.1	8
86	Treating Paget's Diseaseâ€"Why and How Much?. Journal of Bone and Mineral Research, 2017, 32, 1163-1164.	2.8	8
87	Bisphosphonateâ€Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome. JBMR Plus, 2020, 4, e10374.	2.7	8
88	Recovery From Skeletal Fluorosis. Journal of Bone and Mineral Research, 2007, 22, 1475-1475.	2.8	7
89	Obstetric interventions for women with type 1 or type 2 diabetes. International Journal of Gynecology and Obstetrics, 2013, 123, 50-53.	2.3	7
90	Pagetâ€™s disease of bone. Expert Review of Endocrinology and Metabolism, 2009, 4, 651-668.	2.4	6

#	Article	IF	Citations
91	Socioeconomic status and risk factors for complications in young people with type 1 or type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Research and Care, 2021, 9, e002485.	2.8	5
92	Osteomalacia after pamidronate for Paget's disease. Lancet, The, 1994, 343, 855.	13.7	4
93	Insulin use and new diabetes after acceptance for bariatric surgery: comparison of outcomes after completion of surgery or withdrawal from the program. BMJ Open Diabetes Research and Care, 2020, 8, e001837.	2.8	4
94	Severe proton pump inhibitorâ€induced hypomagnesaemia in a mother and daughter. Internal Medicine Journal, 2017, 47, 341-342.	0.8	3
95	Juvenile Pagetâ€™s disease with compound heterozygous mutations in TNFRSF11B presenting with recurrent clavicular fractures and a mild skeletal phenotype. Bone, 2020, 130, 115098.	2.9	3
96	The deleted in colorectal carcinoma (DCC) gene 201 R â†' G polymorphism: no evidence for genetic association with autoimmune disease. European Journal of Human Genetics, 2003, 11, 840-844.	2.8	2
97	Response to Comment on Cundy et al. Early Worsening of Diabetic Nephropathy in Type 2 Diabetes After Rapid Improvement in Chronic Severe Hyperglycemia. Diabetes Care 2021;44:e55â€“e56. Diabetes Care, 2021, 44, e112-e112.	8.6	2
98	Impact of Bariatric Surgery on Unplanned Hospital Admissions for Infection. Obesity Surgery, 2022, 32, 1896-1901.	2.1	2
99	Bone Density Testing in Older Women. JAMA - Journal of the American Medical Association, 2012, 308, 1428.	7.4	1
100	Republished: Paget's disease of bone: clinical review and update. Postgraduate Medical Journal, 2014, 90, 328-331.	1.8	1
101	Advances in the molecular pharmacology and therapeutics of bone disease and international symposium on paget's disease. IBMS BoneKEy, 2009, 6, 439-445.	0.0	0
102	Tumoral Calcinosis in a Patient on Peritoneal Dialysis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1799-1799.	3.6	0
103	Authors' reply to Hodson and colleagues. BMJ, The, 2014, 348, g2692-g2692.	6.0	0
104	Clinical Perspectives of Pagetâ€™s Disease of Bone. , 2016, , 1-14.		0